Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
Provided By GlobeNewswire
Last update: Aug 13, 2024
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –
– Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 –
Read more at globenewswire.com1.31
-0.1 (-7.42%)
Find more stocks in the Stock Screener
SNTI Latest News and Analysis
